NCT05640687

The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar Proteinosis in Vitro

The Study of Mesenchymal Stem Cells Treat Autoimmune Pulmonary Alveolar in Vitro

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 26 (actual)
• Sponsor: Guangzhou Institute of Respiratory Disease · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Autoimmune pulmonary alveolar proteinosis (aPAP) is a respiratory disease characterized by massive deposition of pulmonary surfactant in the alveoli, involving a variety of immune cells and factor disorders. However, there are certain limits in treatment at present. MSCs can improve the microenvironment in the alveoli by regulating immunity, thereby achieving a good therapeutic effect. The purpose of this study is to use the lavage fluid obtained after whole lung lavage with aPAP to isolate alveolar macrophages, and to use MSC to complete the verification of the efficacy of aPAP primary alveolar macrophages in vitro. A series of protocols including multi-factor detection, cell phenotype analysis and phagocytosis assay were used to evaluate the efficacy of MSCs on alveolar macrophages.

Conditions

• Pulmonary Alveolar Proteinosis(PAP)

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-02-01
• Completion: 2023-04-06
• First posted: 2022-12-07
• Last updated: 2023-03-21

Locations

1 site across 1 country: China